This past week was a wacky and wild one for the stem cell field. All kinds of crazy things happened all in one week. What does it all mean? Stem cells the new steroids for sports? Reports surface this week that NY Yankees pitcher Bartolo Colon, had received a non-FDA approved stem cell treatment for […]
A crazy week for stem cells: what the heck does it all mean? Read More »
Today is Friday the 13th, which is supposed to be bad luck, and it seems to be a bad luck day for iPS cells. A paper came out today in Nature that will be highly upsetting for anyone hoping that iPS cells can follow a fairly direct path to the clinic. The paper from Yang
Friday the 13th for iPS cells Read More »
Yesterday I ran a cancer stem cells meeting here at UC Davis School of Medicine. We had some great speakers and over 150 participants including our outstanding keynote speaker, Dr. Jeremy Rich, Director of Stem Cell Research at the Cleveland Clinic. One of the ideas percolating through the meeting was that during cancer development, there
Cancer stem cells and iPS cells Read More »
Why invest in stem cells? Ideas are the foundation of stem cell research, but funding makes those ideas a reality. We talk a lot about governmental funding of stem cell research through CIRM and NIH. The funding from these agencies is essential and will undoubtedly lead to new treatments and cures, possibly for millions of
Why invest in stem cells? Progress, Patients, and Patents Read More »
Since Yamanaka’s discovery of iPS cells first in mouse and then in human cells 5 years ago, both made using viral transduction, a host of new methods to make iPS cells have been reported. These methods are quite diverse, ranging from transposons, to recombinant proteins, to plasmids, and to RNA. Often times these new approaches
Why miRNA iPS cells might be the ticket: an A+ paper Read More »
There are a lot of myths in the stem cell field, some even embraced by some stem cell scientists such as the notion that teratoma are always benign. But when we start talking about translating stem cell technology into the clinic, to the bedside, it is especially important to cast aside our myths, no
Myth of Perfect Stem Cell: meaning for ACT, Geron and field Read More »
It seems reasonably likely that in the end, the final say on the embryonic stem cell case one way or another will be decided by the U.S. Supreme Court. While yesterday brought a victory for science and patients and logic, this was just one battle, not the war. The war that opponents of ES cell
How would the Supreme Court rule on embryonic stem cells? Read More »
A Federal Appeals Court ruled 2-1 today to overturn Judge Lamberth’s injunction against federal funding of ES cell research. Great news! You can read the decision here (warning: big pdf). A key part of the ruling was the following: “the plaintiffs are unlikely to prevail because Dickey-Wicker is ambiguous and the NIH seems reasonably to
Victory for science and patients: what the appeals court ES cell ruling means (UPDATE) Read More »
Tweets from a stem cell? Is that possible? This is one of my favorite pieces and a reader favorite getting hundreds of hits! Let me know what you think. If a stem cell could talk, what would it say (tweet?) I imagine stem cells like teenagers. So much potential but at times difficult. Below is
Greatest Hits: Tweets from a stem cell Read More »
Who’s who in the field of iPS cells? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »